Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Bright-field metallography assay detects HER2 status and protein expression in breast cancer
March 2nd, 2006
A bright-field metallography assay allows concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. According to a study from the United States, "Fluorescence in situ hybridization (FISH) has both excellent sensitivity and specificity in detecting HER2 gene amplification in invasive breast carcinoma. FISH has not been widely implemented in clinical practice because of reagent costs and the special instrumentation and expertise required to perform and integrate the assay. Immunohistochemistry (IHC) for HER2 protein is widely used, but false-positive and false-negative results are problematic. We developed a bright-field assay...
Source: Women's Health Weekly (2006-03-02)
|
